Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center

Justin M Watts, MD, Ashwin Kishtagari, MBBS [Co-first author], Sean Devlin, PhD, Eytan M Stein, MD, Jae H Park, MD, Mario E Lacouture, MD, Martin Tallman, MD

Blood (2013) 122 (21): 5274.

https://doi.org/10.1182/blood.V122.21.5274.5274

Published: 2013

Journal Articles

BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 471.

https://doi.org/10.1182/blood.V116.21.471.471

Published: 2010

Journal Articles

Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75

Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Donna E. Hogge, MD, PhD, Martin Tallman, MD, Tibor Kovacsovics, MD, Lloyd E. Damon, MD, Ellen Ritchie, MD, Rami S. Komrokji, MD, Arthur C. Louie, MD, Eric J Feldman, MD

Blood (2010) 116 (21): 655.

https://doi.org/10.1182/blood.V116.21.655.655

Published: 2010

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study.

Sherif Farag, MD, PhD, Kati Maharry, MAS, Waleska S. Perez, MPH, Mei-Jie Zhang, PhD, John F. DiPersio, MD, PhD, Donald Bunjes, MD, Guido Marcucci, M.D., Maria R. Baer, M.D., Richard A. Larson, MD, Martin Tallman, MD, Clara D. Bloomfield, M.D., Daniel J. Weisdorf, MD

Blood (2009) 114 (22): 657.

https://doi.org/10.1182/blood.V114.22.657.657

Published: 2009

Journal Articles

Optimizing the CD34+ Cell Dose for Allogeneic Transplantation.

J. Mehta, Andrew M Evens, DO, MS, J. Altman, O. Frankfurt, Martin Tallman, MD, L. Gordon, S. Williams, J. Winter, J. Krishnamurthy, S. Duffey, V. Singh, R. Meagher, S. Singhal

Blood (2008) 112 (11): 1118.

https://doi.org/10.1182/blood.V112.11.1118.1118

Published: 2008

Journal Articles

Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research

Selina Luger, MD, Olle Ringden, MD, Waleska S. Peréz, MPH, Mei-Jie Zhang, PhD, John F. DiPersio, MD, PhD, Jorge Sierra, MD, Martin Tallman, MD, Daniel J. Weisdorf, MD, Michael Pulsipher, MD

Blood (2008) 112 (11): 348.

https://doi.org/10.1182/blood.V112.11.348.348

Published: 2008

Journal Articles

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Veena Shankaran, MD, June McKoy, MD, MPH, JD, Ben Djulbegovic, MD, PhD, Allison Lyons, BA, Ken Carson, MD, Cara Tigue, BA, Neal Dandade, BA, Martin Tallman, MD, Oliver Sartor, MD, Charles Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3340.

https://doi.org/10.1182/blood.V110.11.3340.3340

Published: 2007

Journal Articles

Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.

Blood (2007) 110 (11): 3049.

https://doi.org/10.1182/blood.V110.11.3049.3049

Published: 2007

Journal Articles

Unrelated Donor (URD) Hematopoietic Stem Cell Transplantation (HCT) for Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis.

David I. Marks, MD, PhD, Waleska S. Pérez, MPH, Vincent He, MS, Mei-Jie Zhang, PhD, Armand Keating, MD, Martin Tallman, MD, Jorge Sierra, MD, Daniel Weisdorf, MD

Blood (2007) 110 (11): 3055.

https://doi.org/10.1182/blood.V110.11.3055.3055

Published: 2007

Journal Articles

Allogeneic Stem Cell Transplantation (AlloSCT) for the Treatment of Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR).

Mark Litzow, MD, Waleska S. Pérez, MPH, Sergey Tarima, PhD, Armand Keating, MD, Jorge Sierra, MD, Martin Tallman, MD, Daniel Weisdorf, MD

Blood (2007) 110 (11): 3057.

https://doi.org/10.1182/blood.V110.11.3057.3057

Published: 2007

Journal Articles

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

Elihu Estey, MD, Zhuoxin Sun, MD, Jacob Rowe, MD, Stefan Faderl, MD, Peter Cassileth, MD, George Sartiano, MD, Anthony Tartaglia, MD, Guillermo Garcia-Manero, MD, Larry Cripe, MD, John Bennett, MD, Hagop Kantarjian, MD, Martin Tallman, MD

Blood (2007) 110 (11): 298.

https://doi.org/10.1182/blood.V110.11.298.298

Published: 2007

Journal Articles

Obesity in Newly Diagnosed Childhood Acute Promyelocytic Leukemia.

James Feusner, MD, Haesook Kim, PhD, John Gregory, MD, Todd Alonzo, PhD, William Woods, MD, Howard Weinstein, MD, Martin Tallman, MD

Blood (2006) 108 (11): 4494.

https://doi.org/10.1182/blood.V108.11.4494.4494

Published: 2006

Journal Articles

A Randomized, Placebo-Controlled, Double Blind Trial of the MDR Modulator, Zosuquidar, during Conventional Induction and Post-Remission Therapy for Pts > 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS): ECOG 3999.

Larry D. Cripe, MD, Xiaochun Li, PhD, Mark Litzow, MD, Elisabeth Paietta, Jacob M. Rowe, MD, Selina Luger, MD, Martin Tallman, MD

Blood (2006) 108 (11): 423.

https://doi.org/10.1182/blood.V108.11.423.423

Published: 2006

Journal Articles

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

John Gregory, MD, Haesook Kim, PhD, Todd Alonzo, MD, Rob Gerbing, PhD, Angela Ogden, MD, William Woods, MD, Howard Weinstein, MD, Lois Shepherd, MD, Charles Schiffer, MD, Frederick Appelbaum, MD, Cheryl Willman, MD, Peter Wiernik, MD, Jacob Rowe, MD, Martin Tallman, MD, James Feusner, MD

Blood (2005) 106 (11): 894.

https://doi.org/10.1182/blood.V106.11.894.894

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center

BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia

Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study.

Optimizing the CD34+ Cell Dose for Allogeneic Transplantation.

Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.

Unrelated Donor (URD) Hematopoietic Stem Cell Transplantation (HCT) for Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis.

Allogeneic Stem Cell Transplantation (AlloSCT) for the Treatment of Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR).

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

Obesity in Newly Diagnosed Childhood Acute Promyelocytic Leukemia.

A Randomized, Placebo-Controlled, Double Blind Trial of the MDR Modulator, Zosuquidar, during Conventional Induction and Post-Remission Therapy for Pts > 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS): ECOG 3999.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only